Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -252.32M | -257.59M | -283.43M | -279.42M | -292.30M |
| Total Depreciation and Amortization | 13.18M | 13.64M | 13.88M | 14.25M | 14.25M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 70.46M | 69.66M | 88.59M | 83.22M | 85.44M |
| Change in Net Operating Assets | -28.65M | -26.01M | -36.35M | -46.77M | -34.38M |
| Cash from Operations | -197.33M | -200.30M | -217.31M | -228.72M | -226.99M |
| Capital Expenditure | -785.00K | -694.00K | -618.00K | -201.00K | -489.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 60.52M | 76.38M | 88.83M | 130.14M | 72.98M |
| Cash from Investing | 59.73M | 75.69M | 88.22M | 129.94M | 72.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 123.39M | 114.40M | 108.81M | 112.41M | 95.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.63M | 2.28M | 2.28M | 2.28M | -- |
| Cash from Financing | 129.02M | 116.68M | 111.09M | 114.69M | 95.61M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.58M | -7.94M | -18.01M | 15.91M | -58.89M |